Back to Back Issues Page
Low Level Laser Therapy Study to Treat Dry AMD
April 28, 2017
Hello

Low Level Laser Therapy Study to Treat Dry AMD

While most macular degeneration research targets the leaky blood vessels of wet macular degeneration, the truth is that most people with age related macular degeneration have the dry form.

According to the American Macular Degeneration Foundation, approximately 85% to 90% of the cases of macular degeneration are the dry type. With the "dry" form of AMD there is no leakage of fluid or blood from fragile blood vessels around the macula.

Symptoms of Dry AMD

That doesn't mean those with the dry type do not suffer from any vision loss or changes. Symptoms of dry AMD may include:

blurred vision,
loss of detailed or sharp vision,
loss of contrast sensitivity, and
a "smudge" appearing in the center of one's vision.

Laser Treatment for Dry AMD

There is no standard medical treatment for dry AMD. However, we are beginning to see more clinical trials for this type of retinal disease. One of them is called Low Level Laser Therapy (LLLT). LumiThera, a medical device company, offers a non-invasive therapy called photobiomodulation (PBM). This April LumiThera was awarded the "MOST INNOVATIVE AND PROMISING MEDTECH & E-HEALTH COMPANY" during Biovision 2017 in Lyon, France.

Photobiomodulation (PBM) uses a low level laser therapy to treat dry AMD. Unlike hot laser therapy that destroys tissue, this therapy uses low level light therapy to cause a photochemical reaction.

How Does Photobiomodulation Work?

According to LumiThera, "Photobiomodulation (PBM) also known as low level laser therapy (LLLT) has both primary and secondary effects on cellular responses to disease including anti inflammatory, anti oxidant and anti apoptosis (cell death) effects. " Clinical data from 42 eyes that were treated with PBM in the TORPA II study was presented at the Association for Research in Vision and Ophthalmology conference in Seattle May 5, 2016.

Results demonstrated a significant improvement in mean visual acuity of 5.90 letters, improved contrast sensitivity and reduction in drusen size. Find out how this new therapy works and about its latest clinical trial, LIGHTSITE 1 to prevent the progression of dry AMD here:

Low Level Laser Therapy Study with LumiThera

Leslie Degner, RN, BSN

Better Health for Better Vision

www.WebRN-MacularDegeneration.com

Back to Back Issues Page